RAPS: Radial artery outperforms
saphenous vein graft in coronary artery bypass graft patients
Providing the first five-year data from a randomized,
multicenter study examining the best conduit for coronary artery bypass graft
(CABG) surgery, a Canadian research team found that the radial artery outperformed
the saphenous vein, with the former leading to reduced rates of functional graft
occlusion or complete graft occlusion according to research presented at the American
College of Cardiology's 60th Annual Scientific Session.
The study was conducted at 13 centers across Canada and enrolled 561 patients
who underwent CABG surgery for three-vessel disease. Each patient received both
a radial artery graft and a saphenous vein graft at two different diseased vessel
sites. The primary endpoint of functional graft occlusion was determined through
invasive angiography at least five years after surgery. The secondary endpoint
was complete graft occlusion determined through invasive angiography or computed
tomography angiography.
The research team conducted late angiography on 440 patients alive
at one year and on 269 patients at a mean of 7.6 years post-procedure.
In the latter follow up, the researchers found that significantly
fewer radial arteries became partially occluded than saphenous vein
grafts, at 12.0 percent and 18.8 percent, respectively (p = 0.05,
odds ratio [OR] 0.64, 95 percent confidence interval [CI] 0.41 -
0.98). Significantly fewer radial arteries also became completely
occluded, at 8.9 percent, than saphenous veins, at 17.8 percent
(p = 0.004, OR 0.50, 95 percent CI 0.32- 0.80).
In the researchers' previously published one-year results, complete graft occlusion
was significantly reduced in the radial artery compared to the saphenous vein,
while partial graft occlusion was similar between the two conduits.
"Our study shows that the radial artery does seem to offer an improvement
in graft patency compared to vein grafts," said Stephen Fremes, M.D., MSc,
lead study author and head of the Division of Cardiac and Vascular Surgery, Schulich
Heart Centre, at Sunnybrook Health Sciences Centre in Toronto.
Cardiac specialists have long debated which conduit provides better long-term
graft outcomes. Many believe that the radial artery is superior to the saphenous
vein because arterial grafts develop fewer diseases and better withstand aortic
pressure. However, most of the studies proving this have been done using the left
internal thoracic artery, not the radial artery.
"The left internal thoracic artery was shown in the 1980s to be superior
to a vein graft, and as a result, there was a wave of enthusiasm to use this artery
- as well as other arteries - for either more complete arterial revascularization
or total arterial revascularization," Fremes said. "The radial artery
possesses some advantages relative to the internal thoracic artery; it has thicker
walls, which makes suturing easier, and a greater length that can reach all targets
on the heart."
In addition to finding lower rates of occlusion in the radial artery grafts,
the research team also found that radial artery grafts worked better when grafted
to more thoroughly diseased vessels. Specifically, the researchers separated the
target vessels into three groups: those with 70-89 percent narrowing, 90-99 percent
narrowing, and 100 percent narrowing. They found a much lower failure rate (approximately
50 percent) for radial artery grafts that were grafted to vessels with 90 percent
narrowing or more.
"The implications from our one-year study were confirmed in the five-year
results - radial artery bypass grafts should be used preferentially
for the most severely narrowed coronary arteries," Fremes said.
Fremes noted that because each study patient received both graft types, the
researchers were unable to associate clinical outcomes with a specific grafting
strategy. He added that late findings from an Australian study and a study conducted
by the Veterans Affairs Cooperative Studies program will provide both angiographic
and clinical outcomes.
The study was funded by the Canadian Institutes of Health Research. Fremes
had no financial disclosures related to the study.
|